Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shinya Oki

Showing results (61-70 of 72) with videos related to

Pageof 8
Sort By:
Oncotarget|April 19, 2017
Oncogenic histone methyltransferase EZH2: A novel prognostic marker with therapeutic potential in endometrial cancerShinya Oki, Kenbun Sone, Katsutoshi Oda, et al.
Biochemical and Biophysical Research Communications|April 9, 2019
Histone methyltransferase SMYD2 selective inhibitor LLY-507 in combination with poly ADP ribose polymerase inhibitor has therapeutic potential against high-grade serous ovarian carcinomasAsako Kukita, Kenbun Sone, Katsutoshi Oda, et al.
Oncology Letters|October 19, 2018
Kaempferol, a natural dietary flavonoid, suppresses 17β-estradiol-induced survivin expression and causes apoptotic cell death in endometrial cancerAgapiti Hipoliti Chuwa, Kenbun Sone, Katsutoshi Oda, et al.
Cancer Science|April 17, 2023
The pathogenic role of the BRCA2 c.7847C>T (p.Ser2616Phe) variant in breast and ovarian cancer predispositionKazuki Yamazawa, Kokichi Sugano, Kohji Tanakaya, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 3, 2024
HKDC1, a target of TFEB, is essential to maintain both mitochondrial and lysosomal homeostasis, preventing cellular senescenceMengying Cui, Koji Yamano, Kenichi Yamamoto, et al.
Oncotarget|September 24, 2016
MDM2 is a potential therapeutic target and prognostic factor for ovarian clear cell carcinomas with wild type TP53Chinami Makii, Katsutoshi Oda, Yuji Ikeda, et al.
Cancers|November 11, 2022
The Histone Methyltransferase SETD8 Regulates the Expression of Tumor Suppressor Genes via H4K20 Methylation and the p53 Signaling Pathway in Endometrial Cancer CellsAsako Kukita, Kenbun Sone, Syuzo Kaneko, et al.
Nature Genetics|January 18, 2023
Cross-ancestry genome-wide analysis of atrial fibrillation unveils disease biology and enables cardioembolic risk predictionKazuo Miyazawa, Kaoru Ito, Masamichi Ito, et al.
Nucleic Acids Research|November 26, 2024
Update of the FANTOM web resource: enhancement for studying noncoding genomesTomoe Nobusada, Chi Wai Yip, Saumya Agrawal, et al.
Cell Reports|March 2, 2022
Age-associated decline of MondoA drives cellular senescence through impaired autophagy and mitochondrial homeostasisHitomi Yamamoto-Imoto, Satoshi Minami, Tatsuya Shioda, et al.
Pageof 8

Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
Oncotarget|April 19, 2017
Oncogenic histone methyltransferase EZH2: A novel prognostic marker with therapeutic potential in endometrial cancerShinya Oki, Kenbun Sone, Katsutoshi Oda, et al.
Biochemical and Biophysical Research Communications|April 9, 2019
Histone methyltransferase SMYD2 selective inhibitor LLY-507 in combination with poly ADP ribose polymerase inhibitor has therapeutic potential against high-grade serous ovarian carcinomasAsako Kukita, Kenbun Sone, Katsutoshi Oda, et al.
Oncology Letters|October 19, 2018
Kaempferol, a natural dietary flavonoid, suppresses 17β-estradiol-induced survivin expression and causes apoptotic cell death in endometrial cancerAgapiti Hipoliti Chuwa, Kenbun Sone, Katsutoshi Oda, et al.
Cancer Science|April 17, 2023
The pathogenic role of the BRCA2 c.7847C>T (p.Ser2616Phe) variant in breast and ovarian cancer predispositionKazuki Yamazawa, Kokichi Sugano, Kohji Tanakaya, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 3, 2024
HKDC1, a target of TFEB, is essential to maintain both mitochondrial and lysosomal homeostasis, preventing cellular senescenceMengying Cui, Koji Yamano, Kenichi Yamamoto, et al.
Oncotarget|September 24, 2016
MDM2 is a potential therapeutic target and prognostic factor for ovarian clear cell carcinomas with wild type TP53Chinami Makii, Katsutoshi Oda, Yuji Ikeda, et al.
Cancers|November 11, 2022
The Histone Methyltransferase SETD8 Regulates the Expression of Tumor Suppressor Genes via H4K20 Methylation and the p53 Signaling Pathway in Endometrial Cancer CellsAsako Kukita, Kenbun Sone, Syuzo Kaneko, et al.
Nature Genetics|January 18, 2023
Cross-ancestry genome-wide analysis of atrial fibrillation unveils disease biology and enables cardioembolic risk predictionKazuo Miyazawa, Kaoru Ito, Masamichi Ito, et al.
Nucleic Acids Research|November 26, 2024
Update of the FANTOM web resource: enhancement for studying noncoding genomesTomoe Nobusada, Chi Wai Yip, Saumya Agrawal, et al.
Cell Reports|March 2, 2022
Age-associated decline of MondoA drives cellular senescence through impaired autophagy and mitochondrial homeostasisHitomi Yamamoto-Imoto, Satoshi Minami, Tatsuya Shioda, et al.
Pageof 8